The mission of ISCaP is:

- to provide an international forum for research and development in cancer chemoprevention and early diagnosis (screening).

- to hold meetings to promote interaction among laboratory, epidemiological and clinical researchers in cancer chemoprevention and early detection.

- to conduct educational activities to enhance professional and public understanding of cancer chemoprevention and early cancer detection.
Conference Overview

The International Scientific Committee and the Executive Board of ISCaP, the International Society of Cancer Prevention, together with the organizers of the 16th Barcelona World Congress on Gastrointestinal Cancer (WCGC), jointly invite you to both the 8th bi-annual ISCaP conference on Gastrointestinal Cancer Prevention on June 24-25, 2014, and the 16th WCGC on June 25-28, 2014. This year’s ISCaP conference has a particular focus on the prevention of lower (colorectal) GI-cancers, and will include both primary prevention (chemoprevention) and secondary prevention (screening) of colon and rectal cancers.

Both the ISCaP and WCGC conference will be held at the same site, the International Conference Center in Barcelona, Spain. To maximize participation and interaction, the 8th International Conference on Clinical Cancer Prevention and its closing Consensus Conference on the optimal prevention of colon cancer will take place immediately prior to, and partially overlapping with, the start of the 14th World Congress on Gastrointestinal Cancers.

Goals

1. Review current cancer prevention and early detection strategies for GI cancers, focusing on colorectal cancers, with additional discussions of esophageal and stomach cancers.
2. Facilitate interaction among scientists, and offer a forum for students, fellows, and early cancer prevention scientists to interact with senior leaders in this field. These interactions will stimulate research collaborations, introduce scientists and clinicians currently in training to the cancer prevention community, and inspire research efforts capable of propelling the field of cancer prevention forward.
3. Evaluate current evidence relating to GI cancer prevention, and produce consensus recommendations for the research and practice of colorectal cancer risk assessment, screening, and prevention.

ISCaP Executive Board/Conference Organizers:

Powel Brown, MD PhD
ISCaP President (2013-present)
UT MD Anderson Cancer Center
Houston, TX/USA

Jack Cuzick, PhD
ISCaP Past-President (2005-2013)
Queen Mary University of London
London, UK

Frank Meyskens, MD
ISCaP Past-President (1998-2004)
University of California
Irvine, CA/USA

Hans-Joerg Senn, MD
ISCaP Treasurer & Executive Secretary
Tumor- and Breast Center ZeTuP
St. Gallen, Switzerland

Mangesh Thorat, MBBS, MS, DNB
ISCaP Strategic Planning & Funding Ofc.
Queen Mary, University of London
London, UK
Scope/Educational Objectives

This conference will provide a comprehensive update on the most recent results and progress in laboratory, clinical and epidemiological developments in the fields of molecular biology and genetics for GI-cancers (with a special focus on colon cancers) and their interactions with interdisciplinary clinical colon cancer prevention aspects and activities, such as:

- Preclinical models and experimental cancer prevention
- Cancer prevention and health politics
- Prospects of surrogate endpoints and biomarkers in cancer prevention
- Chemoprevention of GI-cancers (esp. colon cancer)
- International consensus meeting on the chemoprevention of colon cancers

Conjoining Society/Conference

In order to maximize attendance, participation, and representation of leaders in the field of gastrointestinal cancer prevention, the 8th biennial ISCaP meeting has been scheduled to immediately precede the 16th World Congress in Gastrointestinal Cancer (WCGC), supported by the European Society for Medical Oncology (ESMO), which is being held June 25th-28th 2014 at the same venue (Centre de Convenciones International de Barcelona) as the ISCaP conference. The WCGC/ESMO program announcement can be accessed through the conference organizer IMEDEX at: www.worldgicancer.com.

Target Audience

This conference and the adjoining WCGC meeting should be of interest to physicians, scientists, clinicians, nurses, students interested in or practicing preventive and clinical oncology (particularly gastrointestinal cancer prevention and early therapy) at all stages of their educational and professional careers.

Educational Methods

This conference will use multiple methods of communication and interaction, including:

- formal presentations by internationally recognized experts in the field;
- panel discussions;
- interactive sessions fostering communication between early investigators and senior leaders in the cancer prevention community;
- presentations of selected abstracts;
- poster sessions
- and informal networking.

To maximize novice-expert interaction, the conference will feature an interactive session wherein junior clinicians and scientists will have the opportunity to meet individually with established faculty to discuss their research ideas and goals and receive expert, relevant career advice. The sessions dedicated to the development of a colorectal cancer prevention consensus statement will be based on the information presented in the formal presentations, panel discussions with comments from the audience, and an interactive session among presenters and other experts to develop the consensus statement. The current meeting program is outlined in this brochure, which can be viewed on the St.Gallen Oncology Conferences (SONK) www.oncoconferences.ch, ISCaP (www.iscac.org), WCGC (www.worldgicancer.com) and Mondial-Barcelona websites (iscap2014@mondial-congress.com)
Invited Speakers
The ISCaP Organizing Committee has gathered leading experts from around the world to present and discuss cutting-edge research focused on gastrointestinal cancer prevention, particularly colorectal cancer prevention. The list of speakers and their affiliations is provided in the conference program. Invited speakers were selected based upon their prominence in the field of GI cancer prevention, risk assessment, and early detection, and the relevance of their work to clinical cancer prevention.

Venue
The 8\textsuperscript{th} biennial ISCaP conference will be held at the International Convention Center of Barcelona (Centre de Convencions Internacional de Barcelona, CCIB). The CCIB is located at Rambla de Prim 1-17 in the technology/business heart of Barcelona, Spain, and is a smoke-free facility offering a full range of services.

\textit{Centre de Convencions Internacional de Barcelona - CCIB}
Rambla de Prim 1-17
Plaça de Willy Brandt
E-08019 Barcelona, Spain
Phone: +34 932 301 000
Web: www.ccib.es

Barcelona
Barcelona is a vibrant multi-faceted collection of diverse cultures. Encompassing 7 universities supporting a population of 200,000 students, numerous research institutions comprising a large scientific and medical community, and 24 hospitals/clinics, Barcelona offers a rich mix of both experienced and novice academic researchers and clinicians, which will facilitate the introduction of budding clinicians and scientists to leaders in the field of cancer prevention. More information on Barcelona can be accessed through the Turisme de Barcelona website at: www.barcelonaturisme.com.

Evaluation
A course evaluation will be distributed to all registered attendees of the conference. This form will provide conference participants an opportunity to evaluate and/or comment on the overall value of all events and activities associated with the conference. As in past ISCaP-hosted events, participants are strongly encouraged to provide feedback on the perceived impact of the program content on their knowledge, interest and/or interaction with the scientific community.

Accreditation/Credit Designation
The ISCaP Executive Board/Conference Organizers are currently in the process of applying for accreditation of this conference as a CPD activity by major accreditation councils (e.g., the Accreditation Council of Oncology in Europe (ACOE), and the European Accreditation Council for Continuing Medical Education (EACCME) of the European Union of Medical Specialists (UEMS). The 6\textsuperscript{th} and 7\textsuperscript{th} biennial ISCaP conferences were each granted European endorsement by the UEMS and awarded 12 European Continuing Medical Education Credits (ECMEC), which are recognized by the American Medical Association (AMA) as AMA PRA Category 1 Credits, and are also recognized by accreditation boards in China and Japan. The 7\textsuperscript{th} biennial conference was awarded 9 CME credits by the ACOE. We anticipate the 8\textsuperscript{th} biennial conference will be awarded similar accreditation.

CME Certificates and Attendance Verification Certificates
Certificates awarding the appropriate credit(s) and/or certificates of attendance will be provided to registered participants immediately prior to the adjournment of the conference. In the event that the participant’s departure occurs prior to the scheduled conference adjournment, the certificates awarding credit and documenting partial attendance will be provided upon e-mail-request by info@oncoconferences.ch
A Call for Scientific Abstracts
Registered attendees are invited to submit scientific abstracts related to the conference topic. Abstracts must be no more than 1 page (DIN-A4) in length, and should include the title, a maximum of 5 authors, and all author affiliations. Abstracts must be submitted electronically to Mondial & Cititravel Congresos, by midnight GMT 15th April 2014, and registration fees for attendees submitting abstracts must be paid in full by midnight GMT 1st May 2014. For any additional information, please contact Mondial & Cititravel Congresos by e-mail: iscap2014@mondial-congress.com

Submitted abstracts will be reviewed and ranked by a scientific review committee. The top 30 abstracts will be selected for oral (ranks 1-6) and poster (ranks 7-30) presentations. The final selection of abstracts for either oral presentation (10 minutes) or poster display will be completed by 15th May 2014. Authors of abstracts selected for presentation/display will be notified by midnight GMT 15th May 2014. Abstracts of authors who have not paid the conference registration fees in full by midnight 31st May 2014 will be automatically withdrawn and neither displayed nor published.

2014 Registration Information
On-line registration will be available through midnight GMT 20th June 2014. Specific hours of onsite registration are to be determined. Please contact:

Mondial & Cititravel Congresos, S.L.
Salvador Espru, 77, local 10
08005 Barcelona – Spain
Ph. +34 932 212 955
Fax. +34 932 210 211
E-mail: iscap2014@mondial-congress.com

ISCaP Meeting Registration Fee includes:
- Admission to all sessions of the ISCaP cancer prevention conference (see program schedule)
- Final ISCaP conference program (pocket book), on site
- Welcome cocktail to the ISCaP meeting on Tuesday evening, 24 June, 2014 (on site)

Method(s) of registration and payment:
Registration will be only electronically and payments by:
Bank transfer to Mondial & Cititravel Congresos, Banco Popular. IBAN ES48 0075 3077 1406 0125 4036. BIC code: POPUESMM. Important note: Indicate to your bank, that transfers must be made free of charge for Mondial & Cititravel Congresos, any bank fee will be charged to the participant.
Preferred Payments: By credit card (Visa, Eurocard, Mastercard)
Or then on-site cash payment.

NOTE: Fees listed are in Euros and are for the ISCaP meeting alone; the amounts listed here do not include any registration fees associated with the WCGC meeting.

<table>
<thead>
<tr>
<th>Registration Fees by Date</th>
<th>27th March 2014</th>
<th>28th March 2014 – 12th June 2014</th>
<th>13th – 24th June 2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physician/Scientist</td>
<td>200</td>
<td>250</td>
<td>300</td>
</tr>
<tr>
<td>Student/Trainee/Nurse*</td>
<td>100</td>
<td>150</td>
<td>200</td>
</tr>
<tr>
<td>Industry Delegate</td>
<td>250</td>
<td>350</td>
<td>400</td>
</tr>
</tbody>
</table>

*with letter of recommendation

A receipt and letter of registration confirmation will be sent by e-mail to each registrant within ten working days of receipt of the completed registration application and fee.
Refund/Cancellation Policy
Cancellations received before 31st May, 2014 are subject to an administrative charge of a 20%. No refunds will be awarded on cancellations received after that date. Refund requests should be submitted in writing to Mondial & Cititravel Congresos, see below.

The ISCaP organizing committee reserves the right to cancel any/all activities associated with this conference prior to the scheduled date, due to low enrollment, natural disaster, or other unforeseen circumstances. In the event of cancellation of any/all activities, registered attendees will be notified by either the contact e-mail or telephone number listed on the registration form, and will receive a full refund of the registration fee. The liability of ISCaP is limited to the registration fee and as such, does not cover any other fees and expenses associated with attending the event, including but not limited to travel and hotel expenses. The ISCaP organizing committee reserves the right to limit the number of attendees to any part of this conference, and is not responsible for any expenses incurred by individuals without confirmed registrations prior to the event date and for whom space is unavailable.

For additional information, contact:
Mondial & Cititravel Congresos, S.L.
Salvador Espriu, 77, local 10
08005 Barcelona – Spain
Ph. +34 932 212 955
Fax. +34 932 210 211
E-mail: iscap2014@mondial-congress.com

Special Assistance
The International Convention Center of Barcelona (CCIB) is an ADA compliant facility that provides reasonable accommodations for persons with disabilities. All entrances and conference rooms are accessible via wheelchair. Sign-language translators will be available for all sessions to provide support for hearing impaired attendees.

Accommodation
The CCIB is situated along the Ronda Litoral, Barcelona’s coastal ring road, and is in close proximity to two dozen hotel facilities. A number of these hotels, along with star ratings and both single- and double-occupancy room rates, are listed on the websites of the:

- CCIB: http://www.ccib.es/getting-to-the-ccib/hotels; and
- Turisme de Barcelona: http://www.barcelonaturisme.com/Where-to-sleep/_3Ngb8YjSpL0PiICYsPhH_Td5EJCxUiHy3DwIsS9r0x!).

Ground Transportation
The CCIB is accessible by both public (local and regional trains, tram, metro, taxi, airport shuttle, and bus) and private transportation. More information and a map of the area can be accessed at the websites of:

- CCIB: http://www.ccib.es/getting-to-the-ccib/location; and
- Turisme de Barcelona: http://www.barcelonaturisme.com/Getting-around-the-city/_3Ngb8YjSpL11Ng1aYD0Ee4wpBvhPzFMvxDr-TzSgxqlg.
International Scientific Committee Members
Chairman: Powel Brown, Houston, TX/USA

Members:
Nadir Arber, Tel-Aviv, Israel
Sir John Burn, Newcastle upon Tyne, UK
Jack Cuzick, London, UK
Andrew Dannenberg, New York, NY, USA
Ray DuBois, Tempe, AZ, USA
Rebecca Fitzgerald, Cambridge, UK
Leslie Ford, Rockville, MD, USA
Ernest Hawk, Houston, TX, USA
Felix Leung, Los Angeles, CA, USA
Frank Meyskens, Irvine, CA, USA
Hans-Joerg Senn, St.Gallen, Switzerland
Asad Umar, Rockville, MD, USA
Cornelia Ulrich, Heidelberg, Germany
Tim Wang, New York, NY, USA
Sir Nick Wright, London, UK.

Important Dates
Discounted Priority Registration Deadline midnight GMT 27th March 2014
Discounted Early Registration Deadline midnight GMT 12th June 2014
Online Registration Deadline midnight GMT 20th June 2014
Abstract Submission Deadline midnight GMT 15th April 2014
Abstract Presenter Registration Deadline midnight GMT 1st May 2014
Abstract Notifications E-mailed midnight GMT 15th May 2014
Conference Presentation Dates 24th – 25th June 2014

*Important Note: Tuesday, 24th June 2014, is a bank holiday in the Catalonia region of Spain, honoring the life of Saint John the Baptist. Please make your travel and banking plans accordingly.*

Contact Us
Before the conference: Mondial & Cititravel Congresos, S.L.
Salvador Espriu, 77, local 10 - 08005 Barcelona – Spain
Ph. +34 932 212 955 - Fax. +34 932 210 211
E-mail: iscap2014@mondial-congress.com

During the conference: Mondial & Cititravel Congresos registration table: Specific hours of onsite registration to be determined. Please contact Mondial & Cititravel Congersos (iscap2014@mondial-congress.com), or check the SONK-website (www.oncoconferences.ch) or ISCaP-website (www.iscac.org) as the conference approaches.
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Chair</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 – 08:05</td>
<td>Greetings and Opening Statements for the 8th Biennial ISCaP Conference</td>
<td>Greetings and Opening Statements for the 8th Biennial ISCaP Conference</td>
<td>ISCaP President &amp; Conference Chair: Powel Brown, Clinical Cancer Prevention, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA</td>
<td>Powel Brown</td>
</tr>
<tr>
<td>08:05 – 08:10</td>
<td>Session 1</td>
<td>Opening Statements: Colorectal Tumorigenesis: State of the Science</td>
<td>Opening Statements: Colorectal Tumorigenesis: State of the Science</td>
<td>Frank Meyskens, Chao Family Comprehensive Cancer Center, University of California, Irvine, California, USA</td>
</tr>
<tr>
<td>08:10 – 08:30</td>
<td>Colorectal Carcinogenesis</td>
<td>Colorectal Carcinogenesis</td>
<td>Colorectal Carcinogenesis</td>
<td>Ray DuBois, The Biodesign Institute, Arizona State University, Tempe, Arizona, USA</td>
</tr>
<tr>
<td>08:30 – 08:50</td>
<td>Colorectal Genetics &amp; Genetic Testing</td>
<td>Colorectal Genetics &amp; Genetic Testing</td>
<td>Colorectal Genetics &amp; Genetic Testing</td>
<td>Cornelia Ulrich, Preventive Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany</td>
</tr>
<tr>
<td>08:50 – 09:10</td>
<td>Molecular Markers of High-Risk Adenomas</td>
<td>Molecular Markers of High-Risk Adenomas</td>
<td>Molecular Markers of High-Risk Adenomas</td>
<td>Sir Nick Wright, Histopathology Laboratory, Cancer Research UK London Research Institute, London, UK; and Barts Cancer Institute, Barts and the London School of Medicine and Dentistry, London, UK</td>
</tr>
<tr>
<td>09:10 – 09:15</td>
<td>Session 2</td>
<td>Opening Statements: Early Detection of Colorectal Cancer</td>
<td>Opening Statements: Early Detection of Colorectal Cancer</td>
<td>Leslie Ford, Division of Cancer Prevention, National Cancer Institute, Rockville, Maryland, USA</td>
</tr>
<tr>
<td>09:15 – 09:35</td>
<td>Screening</td>
<td>Current Status of Imaging for Colorectal Cancer Screening</td>
<td>Current Status of Imaging for Colorectal Cancer Screening</td>
<td>Felix Leung, David Geffen School of Medicine at the University of California, Los Angeles (UCLA), Los Angeles, California, USA</td>
</tr>
<tr>
<td>09:35 – 09:55</td>
<td>Screening</td>
<td>Colon Screening: Colonoscopy and Beyond</td>
<td>Colon Screening: Colonoscopy and Beyond</td>
<td>Urs Marbet, Gastroenterology, Cantonal Hospital of Uri, Altdorf, Switzerland</td>
</tr>
<tr>
<td>09:55 – 10:15</td>
<td>Screening</td>
<td>Molecular Biomarkers to Detect Colon Cancer</td>
<td>Molecular Biomarkers to Detect Colon Cancer</td>
<td>Antoni Castells, Gastroenterology Department, Barnaclinic, Barcelona, Spain</td>
</tr>
<tr>
<td>10:15 – 10:30</td>
<td>Intermission</td>
<td>Tea/Coffee Break</td>
<td>Tea/Coffee Break</td>
<td></td>
</tr>
<tr>
<td>10:30 – 10:35</td>
<td>Session 3</td>
<td>Opening Statements: Colorectal Cancer Prevention</td>
<td>Opening Statements: Colorectal Cancer Prevention</td>
<td>Jack Cuzick, Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK</td>
</tr>
<tr>
<td>Part I:</td>
<td>Targeting Inflammation for Colorectal Cancer</td>
<td>Targeting Inflammation for Colorectal Cancer</td>
<td>Targeting Inflammation for Colorectal Cancer</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>-------------------------------------------------------------------------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:35 – 10:55</td>
<td>Aspirin for the Chemoprevention of Colonic Neoplasia</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Speaker:</td>
<td>Sir John Burn, Institute of Genetic Medicine, Newcastle University, Centre for Life, Newcastle upon Tyne, UK</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:55 – 11:15</td>
<td>Colorectal Cancer Chemoprevention Trials</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:15 – 11:35</td>
<td>DFMO and Sulindac for Colorectal Cancer Prevention</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Speaker:</td>
<td>Frank Meyskens, Chao Family Comprehensive Cancer Center, University of California, Irvine, California, USA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:35 – 11:55</td>
<td>Novel Strategies to Target Inflammatory Pathways</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Speaker:</td>
<td>Eduardo Vilar-Sanchez, Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:55 – 13:30</td>
<td>Intermission: Lunch, Poster Review</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:55 – 13:30</td>
<td>Poster Walk: Informal viewing of poster presentations</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:55 – 13:30</td>
<td>Meet the Faculty: Individual interactive sessions between faculty &amp; junior researchers</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30 – 13:55</td>
<td>Session 4 Opening Statements: Prevention of Upper Gastrointestinal Cancers, Esophageal &amp; Gastric</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chair:</td>
<td>Asad Umar, Gastrointestinal &amp; Other Cancers Research Group, Division of Cancer Prevention, National Cancer Institute, Rockville, Maryland, USA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:35 – 13:55</td>
<td>Prevention of Esophageal Cancer</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Speaker:</td>
<td>Brian Reid, Medicine and Genome Sciences, University of Washington, Seattle, Washington, USA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:55 – 14:15</td>
<td>Barrett's Esophagus: Screening and Prevention</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Speaker:</td>
<td>Rebecca Fitzgerald, Medical Research Council Cancer Cell Unit, Hutchison-Medical Research Council (MRC) Research Centre, Cambridge, UK</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:15 – 14:35</td>
<td>Novel Animal Models of Esophageal Cancer</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Speaker:</td>
<td>Tim Wang, Digestive and Liver Diseases, Columbia University, College of Physicians &amp; Surgeons, New York, New York, USA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:35 – 14:55</td>
<td>Prevention of Gastric Cancer</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:35 – 14:55</td>
<td>Helicobacter Pylori Eradication to Prevent Gastric Cancer</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Speaker:</td>
<td>Peter Malfertheiner, Gastroenterology, Hepatology &amp; Infectious Diseases, Otto-von-Guericke University of Magdeburg, Magdeburg, Germany</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:55 – 15:10</td>
<td>Intermission: Tea/Coffee Break</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:10 – 16:00</td>
<td>Session 5: Selected Abstract Oral Presentations</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chair:</td>
<td>ISCaP President &amp; Conference Chair: Powel Brown, Clinical Cancer Prevention, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:15 – 16:00</td>
<td>Speakers: Panel-selected students, fellows and early investigators</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:15 – 16:00</td>
<td>Focus: Presentation of top-ranking abstracts</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00 – 17:00</td>
<td>Session 6: Panel Discussion – Options for Colorectal Cancer Chemoprevention</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chair:</td>
<td>Powel Brown, Clinical Cancer Prevention, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
16:00 – 17:00  
**Participants:** Speakers and Session Chairs  
**Focus:** Open discussion of current options for the prevention of colorectal cancer to facilitate and enhance the development of a consensus statement in the remaining two sessions

17:00  
**Close of Day’s Events:** Powel Brown  
**Welcome Cocktail & Networking Reception:** Faculty, early investigators, fellows & students

**DAY 2**  
**Wednesday, 25th June 2014**

| 09:00 – 10:30 | **Session 1:** Colorectal Cancer, Open Consensus Session Discussion Session – Part I  
Chair: Powel Brown, Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA  
**Participants:** Faculty - chairs, speakers, panel participants & other experts + registered participants  
**Focus:** Develop a consensus statement for the prevention of colorectal cancer

| 10:30 – 11:00 | **Intermission:** Tea/Coffee Break

| 11:00 – 12:30 | **Session 2:** Colorectal Cancer, Open Consensus Session Discussion Session – Part II  
Chair: Powel Brown, Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA  
**Participants:** Faculty - chairs, speakers, panel participants & other experts + registered participants  
**Focus:** Develop a consensus statement for the prevention of colorectal cancer and outline for the manuscript, to be published

| 12:30 – 13:00 | **Summary and Closing of Conference:** Powel Brown, Houston/TX, USA  
**Individual Lunch & Departure**


About ISCaP

The International Society for Cancer Prevention (ISCaP) is a non-profit organization founded in 1995 to advance cancer prevention research and education by bringing together researchers and clinicians and fostering global collaborations. ISCaP, now under the leadership of Dr. Powel Brown, has hosted 7 biennial meetings under the presidencies of Drs. Umberto Veronesi (1995-1998), Frank Meyskens (1998-2004), and Jack Cuzick (2004-2013). These conferences were co-sponsored by the charitable Foundation St.Gallen Oncology Conferences (SONK, Switzerland), Cancer Research UK (CRUK, London, UK), the European School of Oncology (ESO, Milan, Italy), the European Society for Medical Oncology (ESMO, Viganello-Lugano, Switzerland), the European Cancer Prevention Organization (ECP, Hasselt, Belgium), the European Association for Cancer Research (EACR, Nottingham, UK) and the American Cancer Society (ACS, Atlanta, GA, USA), and have provided a forum for collaboration, education, and interaction to the international cancer prevention community.

Over the last decade ISCaP has invited leading experts from around the world to present and discuss cutting-edge research focused on prevention, particularly chemoprevention, of a broad range of cancers. The special focus of these meetings has been and will continue to be bridging the gap between laboratory-based prevention activities in model systems and large-scale clinical projects. Greater collaboration between these two sectors will facilitate progress across the cancer prevention community by providing clinical investigators with novel mechanistic findings, and laboratory scientists with clinical material supporting mechanistic prevention studies. In addition, these conferences offer an opportunity for students, fellows, and junior faculty to present their research findings. Thus, this conference is a major mechanism to attract early scientists to the field of cancer prevention, to maintain research in this critical area.

The previous ISCaP meetings, held in St. Gallen, Switzerland (1st-6th meetings), and Milan, Italy (7th meeting), were exciting, interactive venues which created an atmosphere conducive for forging the scientific collaborations necessary to propel the field of cancer prevention forward. In addition, each of the last three conferences dedicated a session to the development of a consensus statement on a major topic in cancer prevention: aspirin and non-steroidal anti-inflammatory drugs (5th biennial meeting, 2008) and breast cancer (6th biennial meeting, 2010), both published in the Lancet Oncology. A third consensus statement on the prevention of prostate cancer (7th biennial meeting, 2013) has been submitted for publication. These statements have been well-received by and highly influential within the global scientific community.
Registration Form

Please read the registration conditions before completing this form. Note that any registration has to be guaranteed by the appropriate payment. Use one form per delegate. Please use capital letters. The data included will be used to issue your invoice.

☐ Prof.  ☐ Dr.  FIRST NAME    FAMILY NAME

ORGANISATION / INSTITUTION

ADDRESS

ZIP   CITY   COUNTRY

TEL.   FAX.   E-MAIL

EU VAT NUMBER (for invoicing):

INVOICING DETAILS (if different from above):

In compliance with what is stated in LO 15/99 of Protection of Data of a Personal Nature, we hereby inform you that the personal details that you provide us will be entered into a file of the 8th International ISCaP Conference 2014 on Gastrointestinal Cancer Prevention, for promotion and other matters related to the conference. Completion of this form implies authorization to the 8th International ISCaP Conference 2014 on Gastrointestinal Cancer Prevention to use the personal data supplied for the above mentioned purposes. You may exercise your rights of access, rectification and cancellation, if needed, in our office.

1. Registration Fees (VAT included). Designated payment must be received by midnight GMT for that date

<table>
<thead>
<tr>
<th></th>
<th>On or before 27th March</th>
<th>28th March – 12th June</th>
<th>13th – 24th June</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physician/Scientist</td>
<td>200,00 €</td>
<td>250,00 €</td>
<td>300,00 €</td>
</tr>
<tr>
<td>Student/Trainee/Nurse*</td>
<td>100,00 €</td>
<td>150,00 €</td>
<td>200,00 €</td>
</tr>
<tr>
<td>Industry Delegate</td>
<td>250,00 €</td>
<td>350,00 €</td>
<td>400,00 €</td>
</tr>
</tbody>
</table>

*with letter of recommendation

2. Details of Payment. Your registration will be confirmed only on the receipt of appropriate amount in €, as per the schedule of deadlines outlined under #1 above. Payments shall be made in EURO to Mondial & Cititravel Congresos, S.L., by one of the following procedures:

☐ Bank transfer to Banco Popular. IBAN ES48 0075 3077 1406 0125 4036. BIC code: POPUESMM. Important note: Indicate to your bank, that transfers must be made free of charge for Mondial & Cititravel Congresos, any bank fee will be charged to the participant.

☐ By credit card: ☐ VISA ☐ Eurocard / MasterCard

Credit card number: ____________________________ Expiry date: ____________________________

Name of cardholder: ____________________________

3. Refund/Cancellation Policy

Cancellations received before 31st May, 2014 are subject to an administrative charge of a 20%. No refunds will be awarded on cancellations received after that date. Refund requests should be submitted in writing to Mondial & Cititravel Congresos

I authorize Mondial & Cititravel Congresos to charge my credit card account the total amount of fees as requested on this form. I accept the cancellation policy indicated above:

Date: ____________________________ Signature: ____________________________

4. Contact

Mondial & Cititravel Congresos, S.L. - Salvador Espriu, 77, local 10 - 08005 Barcelona – Spain
Ph. +34 932 212 955 - Fax. +34 932 210 211 - E-mail: iscap2014@mondial-congress.com
Conference Endorsers/Supporters: